AIM shares surge 39.34% premarket on positive Phase 2 pancreatic cancer combo trial data showing 19.7-month survival.

AIM ImmunoTech surged 39.34% in premarket trading following the release of positive Phase 2 interim data for Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. The trial reported a median survival of 19.7 months with Ampligen (vs. 8.6 months with standard care) and no significant toxicity, alongside improved quality of life. The combination therapy demonstrated activation of innate and adaptive immune responses, with 18 of 25 planned patients enrolled. The company highlighted orphan drug designations in the U.S. and EU, patent protection until 2039, and potential for Phase 3 trials, positioning Ampligen as a game-changer in a high-unmet-need market. These developments, emphasizing both efficacy and safety in a lethal disease, likely drove the sharp premarket rally.